AENZ yields 103.09% · ABBV yields 3.09%● Live data
📍 AENZ pulled ahead of the other in Year 1
Combined, AENZ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AENZ + ABBV for your $10,000?
Aenza S.A.A., together with its subsidiaries, engages in the Infrastructure, Energy, Engineering and Construction, and Real Estate management businesses in Peru, Bolivia, Chile, Mexico, and Colombia. The company's Infrastructure segment offers long-term concessions or similar contractual arrangements in Peru for three toll roads, the Lima Metro, a wastewater treatment plant in Lima, four producing oil fields, five multiple fuel storage facilities, and a gas processing plant, as well as operation and maintenance services for infrastructure assets. Its Engineering and Construction segment provides traditional engineering services, such as structural, civil, and design engineering; and services ranging from architectural planning to advanced specialties comprising process design, simulation, and environmental services. This segment also provides services related to civil works, which include construction of hydroelectric power stations and other large infrastructure facilities; electro mechanic construction, such as concentrator plants, oil, and natural gas pipelines, and transmission lines; and building construction comprising office and residential buildings, hotels, affordable housing projects, shopping centers, and industrial facilities, as well as procurement services; maintains plants and industrial facilities; and rents construction equipment. It serves mining, power, oil and gas, transportation, real estate, and other infrastructure sectors. The company's Real Estate segment develops and sells homes, and office and commercial spaces. The company was formerly known as Graña y Montero S.A.A. and changed its name to Aenza S.A.A. in November 2020. Aenza S.A.A. was founded in 1933 and is based in Surquillo, Peru.
Full AENZ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.